Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher K Daugherty

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Cancer|October 8, 2016
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Jonas A de Souza, Bonnie J Yap, Kristen Wroblewski, et al.
Cancer|January 11, 2012
When parents disclose BRCA1/2 test results: their communication and perceptions of offspring responseAngela R Bradbury, Linda Patrick-Miller, Brian L Egleston, et al.
IRB|June 26, 2009
An intervention to improve cancer patients' understanding of early-phase clinical trialsNancy E Kass, Jeremy Sugarman, Amy M Medley, et al.
Leukemia & Lymphoma|June 12, 2010
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantLucy A Godley, Uchenna O Njiaju, Margaret Green, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Parent opinions regarding the genetic testing of minors for BRCA1/2Angela R Bradbury, Linda Patrick-Miller, Brian Egleston, et al.
Blood Advances|January 25, 2018
Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignanciesMichael W Drazer, Sabah Kadri, Madina Sukhanova, et al.
JCO Oncology Practice|February 8, 2021
Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, Mitigation, and ResilienceFay J Hlubocky, Banu E Symington, Daniel C McFarland, et al.
Haematologica|January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsGregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Cancer|October 8, 2016
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)Jonas A de Souza, Bonnie J Yap, Kristen Wroblewski, et al.
Cancer|January 11, 2012
When parents disclose BRCA1/2 test results: their communication and perceptions of offspring responseAngela R Bradbury, Linda Patrick-Miller, Brian L Egleston, et al.
IRB|June 26, 2009
An intervention to improve cancer patients' understanding of early-phase clinical trialsNancy E Kass, Jeremy Sugarman, Amy M Medley, et al.
Leukemia & Lymphoma|June 12, 2010
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplantLucy A Godley, Uchenna O Njiaju, Margaret Green, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Parent opinions regarding the genetic testing of minors for BRCA1/2Angela R Bradbury, Linda Patrick-Miller, Brian Egleston, et al.
Blood Advances|January 25, 2018
Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignanciesMichael W Drazer, Sabah Kadri, Madina Sukhanova, et al.
JCO Oncology Practice|February 8, 2021
Impact of the COVID-19 Pandemic on Oncologist Burnout, Emotional Well-Being, and Moral Distress: Considerations for the Cancer Organization's Response for Readiness, Mitigation, and ResilienceFay J Hlubocky, Banu E Symington, Daniel C McFarland, et al.
Haematologica|January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitorsGregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Pageof 5